Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health launched Take C.H.A.R.G.E., a national registry addressing canine cancer, which coincides with National Canine Cancer Awareness Day on May 23, 2022. Initial data from a Gallup Poll of over 3,500 dog owners reveal a 2.8% incidence of canine cancer—five times greater than humans. Over 80% of respondents advocate for a registry to better understand the disease. The registry aims to gather data from 35,000 canine medical records to enhance diagnosis and treatment, highlighting the need for improved canine healthcare.

Jaguar Health is hosting a media event in NYC on May 23, 2022, to launch the Canine Cancer: Take C.H.A.R.G.E. initiative, the first U.S. Canine Cancer Registry. This registry will assess cancer prevalence in dogs by analyzing anonymized medical records and survey data. The event coincides with the inaugural National Canine Cancer Awareness Day and features veterinary cancer specialists and Broadway performances. The initiative aims to improve understanding of canine cancer, benefiting both pets and potentially human health.

Jaguar Health, Inc. (NASDAQ:JAGX) is hosting an event on May 23, 2022, in New York City to launch the Take C.H.A.R.G.E. initiative, the first U.S. Canine Cancer Registry. This initiative aims to assess the impact of cancer on dogs using data from a Gallup survey and thousands of anonymized medical records. The event will feature presentations by veterinary experts and performances by Broadway stars, emphasizing the importance of canine cancer awareness. This launch coincides with the first annual National Canine Cancer Awareness Day.

Jaguar Health (NASDAQ:JAGX) announced an analyst report issued by TAG Investment Bankers, led by analyst Chris Wickham. This report, reflecting paid research, showcases Jaguar Health's capability in the biotechnology sector. The company, focused on developing plant-based medicines for gastrointestinal issues, holds a majority stake in Napo Therapeutics, an entity working to expand crofelemer access in Europe. The ongoing OnTarget study evaluates crofelemer for adult cancer patients to prevent diarrhea. Jaguar maintains a commitment to sustainable harvesting and developing innovative pharmaceutical solutions.

Jaguar Health (NASDAQ:JAGX) launched a telehealth program for its FDA-approved antidiarrheal drug Mytesi on May 6, 2022. This program aims to enhance patient access, especially for those suffering from HIV-related diarrhea. Patients can connect with healthcare providers using mobile devices at their convenience, eliminating long wait times for consultations. The telehealth service underscores the importance of immediate care in addressing sensitive health issues. Mytesi is intended for adults with noninfectious diarrhea related to HIV/AIDS receiving antiretroviral therapy.

Jaguar Health reported a net revenue of approximately $2.6 million for the first quarter of 2022, marking a 24% increase from the previous quarter and a 112% year-over-year growth. This revenue boost is attributed to the transition to a closed network of specialty pharmacies. The company is focused on ongoing clinical trials for crofelemer, particularly for cancer therapy-related diarrhea, with enrollment expected to complete in the first half of 2023. Future milestones include proof-of-concept studies for short bowel syndrome and congenital diarrheal disorders in 2022-2023.

Jaguar Health, Inc. (NASDAQ:JAGX) announced the grant of 50,000 restricted stock units (RSUs) to Mark Johnson, its newly appointed Senior Vice President of Product Development, effective May 6, 2022. The RSUs will fully vest on the one-year anniversary of his hire, contingent on his continued service with the company. The compensation, approved by the Compensation Committee, serves as an inducement for his acceptance of the position. Jaguar, a commercial-stage pharmaceuticals company, focuses on developing plant-based medications for gastrointestinal distress in humans and animals.

Jaguar Health, Inc. (NASDAQ:JAGX) announced an investor webcast on May 10, 2022, at 8:30 AM ET to discuss first-quarter 2022 financial results and corporate updates. The company plans to file its Earnings Report on Form 10-Q for the quarter ending March 31, 2022. The previous release incorrectly stated the date as March 10. Jaguar Health focuses on developing plant-based, non-opioid pharmaceuticals for gastrointestinal distress in humans and animals. For more details, register here.

Jaguar Health, Inc. (NASDAQ:JAGX) announced an investor webcast on May 10, 2022, at 8:30 AM Eastern Time to discuss first-quarter 2022 financial results and corporate updates. The earnings report will be filed on May 10, 2022, on Form 10-Q. Jaguar focuses on developing plant-based, non-opioid medicines for gastrointestinal issues in both humans and animals. The company is known for its drug candidate, crofelemer, which is currently involved in a pivotal Phase 3 clinical trial for diarrhea in cancer patients receiving targeted therapy.